Fidelity Investments’s X4 Pharmaceuticals XFOR Stock Holding History

Fidelity Investments’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.5M	Sell	8,103,400 -395,700	-5%	-$1.48M	﹤0.01%	1579
2025 Q4	$34M	Buy	+8,499,100	New	+$30.9M	﹤0.01%	1584
2025 Q3	–	Sell	-1,697	Closed	-$3.22K	–	5598
2025 Q2	$3.22K	Buy	1,697 +326	+24%	+$1.33K	﹤0.01%	4787
2025 Q1	$9.72K	Buy	1,371 +1,214	+773%	+$16.7K	﹤0.01%	4507
2024 Q4	$3.45K	Sell	157 -214	-58%	-$3.41K	﹤0.01%	4729
2024 Q3	$7.46K	Buy	371 +251	+209%	+$5.24K	﹤0.01%	4520
2024 Q2	$2.09K	Buy	120 +36	+43%	+$1.18K	﹤0.01%	4719
2024 Q1	$3.52K	Buy	84 +59	+236%	+$1.64K	﹤0.01%	4599
2023 Q4	$620	Sell	25 -28	-53%	-$681	﹤0.01%	4798
2023 Q3	$1.72K	Sell	53 -518	-91%	-$22.6K	﹤0.01%	4572
2023 Q2	$33.2K	Buy	+571	New	+$29.3K	﹤0.01%	3634
2023 Q1	–	Hold	0	–	–	–	5231
2022 Q4	–	Sell	-333	Closed	-$17K	–	5611
2022 Q3	$17K	Buy	+333	New	+$11.5K	﹤0.01%	3915
2022 Q1	–	Sell	-1,768	Closed	-$121K	–	5545
2021 Q4	$121K	Sell	1,768 -3,326	-65%	-$421K	﹤0.01%	3048
2021 Q3	$808K	Sell	5,094 -1,993	-28%	-$328K	﹤0.01%	2727
2021 Q2	$1.38M	Hold	7,087	–	–	﹤0.01%	2610
2021 Q1	$1.83M	Hold	7,087	–	–	﹤0.01%	2488
2020 Q4	$1.37M	Sell	7,087 -310	-4%	-$60.9K	﹤0.01%	2473
2020 Q3	$1.5M	Sell	7,397 -15,863	-68%	-$3.8M	﹤0.01%	2356
2020 Q2	$6.5M	Hold	23,260	–	–	﹤0.01%	1963
2020 Q1	$6.98M	Sell	23,260 -6,740	-22%	-$1.91M	﹤0.01%	1816
2019 Q4	$9.63M	Hold	30,000	–	–	﹤0.01%	1862
2019 Q3	$11.4M	Hold	30,000	–	–	﹤0.01%	1780
2019 Q2	$13.5M	Buy	+30,000	New	+$15.2M	﹤0.01%	1775
2018 Q4	–	Sell	-1	Closed	–	–	4232
2018 Q3	$0	Sell	1 -6,157	-100%	-$2.61M	﹤0.01%	3827
2018 Q2	$4.02M	Sell	6,158 -2,425	-28%	-$7.94M	﹤0.01%	2198
2018 Q1	$35.4M	Sell	8,583 -22	-0.3%	-$64K	﹤0.01%	1453
2017 Q4	$19.8M	Buy	+8,605	New	+$21.8M	﹤0.01%	1732

Other funds holding XFOR

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments's XFOR Position: Q1 2026 in Review

Fidelity Investments reduced its X4 Pharmaceuticals (XFOR) stake by 4.7% in Q1 2026, selling an estimated $1.48M and leaving 8,103,400 shares worth $33.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1579.

Fidelity Investments first reported a position in XFOR in Q4 2017 and has held it in 27 quarters since. The position peaked at $35.4M in Q1 2018. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

Fidelity Investments held 8,103,400 shares of X4 Pharmaceuticals worth $33.5M as of Q1 2026.
Fidelity Investments sold 395,700 X4 Pharmaceuticals shares in Q1 2026, an estimated $1.48M.
X4 Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1579 holding.
Fidelity Investments first reported a position in X4 Pharmaceuticals in Q4 2017 and has held it in 27 quarters since.
Fidelity Investments's X4 Pharmaceuticals position peaked at $35.4M in Q1 2018.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.